Modified GRF(1-29) + Ipamorelin combines two complementary GH-release pathways: GHRH-receptor signaling and GHS/ghrelin-receptor signaling. Research commonly tracks GH pulse dynamics, IGF-1, pathway synergy, and endocrine selectivity versus the individual components.

What this formula features: Modified GRF provides the GHRH signal, while Ipamorelin provides a GHS-receptor signal. Ipamorelin has demonstrated selective GH release in preclinical work with comparatively little ACTH or cortisol release at studied doses; however, controlled human evidence for this exact combination is limited.

Typical research readouts: Researchers typically compare GH pulse amplitude, secretion kinetics, IGF-1 response, receptor-pathway synergy, and endocrine selectivity versus either component alone. Combination effects should be measured directly rather than assumed from single-agent data.

This product is strictly for research purposes only. Not approved for human or animal use.